Cardiac Biomarkers Market, By Type (Myoglobin, Myocardial muscle Creatine Kinase, Brain Natriuretic Peptide (BNPs), Troponins (T and I), NT-proBNP, Ischemia Modified Albumin (IMA)), By Application (Congestive Heart Failure, Myocardial Infarction, Acute Coronary Syndrome, Atherosclerosis), By Location of Testing (Point of Care, Laboratory), By Region Analysis - Global Analysis and Industry Forecast Report Till 2030.

Cardiac Biomarkers Market is projected to grow from $9.42 billion to $28.40 billion, at a CAGR of 12.6% in terms of revenue during the forecast period.

The use of cardiac biomarkers as a comprehensive diagnostic strategy for numerous cardiovascular disorders is very common. The cardiac biomarkers market is mainly segmented by the increasing prevalence of cardiovascular diseases and lifestyle-related diseases, increasing demand for research and treatment of certain diseases using cardiac biomarkers, technological advances in cardiac biomarkers, and support to increase public awareness of cardiac biomarkers. Driven by government initiatives. Cardiovascular disease. Nonetheless, a lack of public awareness is anticipated to impede market expansion.

Heart stress or muscle damage causes the release of cardiac markers, sometimes referred to as cardiac biomarkers, into the bloodstream. A few examples of these markers are cardiac troponins, Creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. These markers can be measured and tested to help with the identification of heart disorders such myocardial ischemia and acute coronary syndrome (ACS). Electrocardiograms (ECGs) and clinical history are currently employed in the triage and diagnostic systems to assess the risk of these disorders.

Cardiac markers and cardiovascular biomarkers play a crucial role in diagnosing and assessing cardiac conditions. Cardiac enzyme markers, such as creatine kinase-MB (CK-MB) and myoglobin, provide valuable insights into myocardial infarction, indicating the extent of cardiac muscle damage. Troponin levels, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), serve as highly sensitive and specific biomarkers for detecting heart muscle injury. Additionally, B-type natriuretic peptide (BNP) and its precursor, N-terminal pro-brain natriuretic peptide (NT-proBNP), offer essential information about cardiac stress and heart failure. Moreover, high-sensitivity C-reactive protein (hs-CRP) aids in assessing inflammation and predicting cardiovascular risk. The utilization of these cardiac markers and cardiovascular biomarkers empowers clinicians to accurately diagnose and manage various cardiac conditions, ultimately improving patient outcomes.

Market Dynamics:

Drivers:

Cardiovascular disease is the leading cause of death worldwide. The American College of Cardiology estimates that an American will experience a myocardial infarction every 40 seconds or so. Diseases like diabetes and hypertension that are influenced by lifestyle are becoming more common. For instance, 1.15 billion individuals worldwide are thought to have hypertension, according to the WHO. Also, the growing number of elderly people who are seriously ill requires regular monitoring, as well as occasional updates to their loved ones on their condition. The benefits of cardiac biomarkers, which help treat cardiovascular disease and other lifestyle diseases, are thereby fueling market expansion.

Restraints:

The study of cardiac biomarkers is still in its early stages. Also, this product is unknown to the majority of people. The slow adoption of biomarkers by physicians is a cardiac biomarkers market restraint. These limits can be removed through study, but that takes time and money. Since that those who survived the COVID pandemic are more likely to develop chronic cardiovascular diseases, the current attention on healthcare that the pandemic brought about internationally potentially stimulate this industry by funding its research. This can then be utilized to spread the word about the product and increase the allure of a straightforward test that can be done at home.

Opportunities:

In response to the COVID-19 outbreak, governments from all over the world have started a number of projects to upgrade the healthcare system. The demand for cutting-edge medical products like cardiac biomarkers diagnostic test kits has increased as healthcare spending has grown, particularly in developing nations like India, South Korea, and Japan. The "National Health Mission" will continue, the Indian government has reportedly agreed, according to the India Brand Equity Foundation (IBEF). To lower world mortality, the government will implement this programme by distributing cutting-edge medical equipment for cardiology, neurology, and other illnesses in rural areas. Several such initiatives are anticipated to open up new market expansion chances.

Key Players:

• F. Hoffmann-La Roche Ltd.

• Thermo Fisher Scientific Inc.

• Abbott

• QIAGEN

• PerkinElmer, Inc.

• Merck KGaA

• Bio-Rad Laboratories, Inc.

• Enzo Biochem, Inc.

• Charles River Laboratories

• Eurofins Scientific 

• Agilent Technologies, Inc.

• Bruker

• Siemens

• Epigenomics AG

• General Electric

Market Segmentation:

Cardiac Biomarkers Market, By Type

• Myocardial muscle Creatine Kinase (CK-MB)

• Troponins (T and I)

• Myoglobin, Brain Natriuretic Peptide (BNPs)

• NT-proBNP

• Ischemia Modified Albumin (IMA)

Cardiac Biomarkers Market, By Application

• Myocardial Infarction

• Congestive Heart Failure

• Acute Coronary Syndrome

• Atherosclerosis

Cardiac Biomarkers Market, By Location of Testing

• Point of Care

• Laboratory

Cardiac Biomarkers Market, By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa (MEA)

Regional Analysis:

Over the projected period, Asia-Pacific is anticipated to develop at the fastest rate. This is due to the high prevalence of diabetes, COPD, and cardiovascular illnesses. More than 60% of all diabetics, according to the American Diabetes Association, reside in Asia. China and India both have large populations. The expansion of the regional industry is also being fueled by numerous initiatives done by governments in the Asia-Pacific to boost the healthcare system. To provide a centralized system for uniquely identifying each participant in the National Health Stack, the Government of India announced the creation of a national health ID for every Indian.

According to a study in the American Journal of Obstetrics and Gynecology, a blood test that uses genetic biomarkers and artificial intelligence (AI) can detect embryonic congenital heart abnormalities early on. The research team evaluated how well different AI techniques combined with genomic data could be used to spot changed gene circuits that were crucial to the emergence of congenital cardiac abnormalities. Findings suggest that a crucial first step in creating successful postnatal action plans for infants at risk is to identify congenital cardiac defects using a minimally invasive technique.

Scope of the report:

User

Tab Content